📣 VC round data is live. Check it out!

Simulations Plus Valuation Multiples

Discover Simulations Plus' revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like Vitalhub, Software Service, Kneat, Ascom and more.

Simulations Plus Overview

About Simulations Plus

Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.


Founded

1996

HQ

United States

Employees

213

Financials (LTM)

Revenue: $81M
EBITDA: $22M

EV

$297M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Simulations Plus Financials

Simulations Plus reported last 12-month revenue of $81M and EBITDA of $22M.

In the same LTM period, Simulations Plus generated $51M in gross profit, $22M in EBITDA, and had net loss of ($9M).

Revenue (LTM)


Simulations Plus P&L

In the most recent fiscal year, Simulations Plus reported revenue of $79M and EBITDA of $22M.

Simulations Plus is unprofitable as of last fiscal year, with gross margin of 58%, EBITDA margin of 28%, and net margin of (82%).

See analyst estimates for Simulations Plus
LTMLast FY202320242025202620272028
Revenue$81M$79M$63M$73M$80M
Gross Profit$51M$46M$46M$44M$48M
Gross Margin63%58%74%60%60%
EBITDA$22M$22M$14M$13M$17M
EBITDA Margin28%28%23%17%22%
EBIT Margin(9%)8%12%9%11%
Net Profit($9M)($65M)$10M($15M)($40M)
Net Margin(11%)(82%)16%(20%)(50%)

Financial data powered by Morningstar, Inc.

Simulations Plus Stock Performance

Simulations Plus has current market cap of $339M, and enterprise value of $297M.

Market Cap Evolution


Simulations Plus' stock price is $16.76.

Simulations Plus share price decreased by 1.9% in the last 30 days, and by 3.9% in the last year.

Simulations Plus has an EPS (earnings per share) of $-3.20.

See more trading valuation data for Simulations Plus
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$297M$339M-5.4%-1.9%41.8%-3.9%$-3.20

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Simulations Plus Valuation Multiples

Simulations Plus trades at 3.7x EV/Revenue multiple, and 13.2x EV/EBITDA.

See NTM and 2027E valuation multiples for Simulations Plus

EV / Revenue (LTM)


Simulations Plus Financial Valuation Multiples

As of June 3, 2026, Simulations Plus has market cap of $339M and EV of $297M.

Simulations Plus has a P/E ratio of (37.8x).

LTMLast FY202320242025202620272028
EV/Revenue3.7x3.8x4.7x4.1x3.7x
EV/EBITDA13.2x13.5x20.8x23.3x17.1x
EV/EBIT(40.6x)45.8x37.8x47.6x34.2x
EV/Gross Profit5.8x6.4x6.4x6.7x6.2x
P/E(37.8x)(5.2x)34.0x(22.7x)(8.4x)
EV/FCF-20.6x20.2x27.5x20.6x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Simulations Plus Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Simulations Plus Margins & Growth Rates

Simulations Plus grew revenue by 3% and EBITDA by 3% in the last fiscal year.

In the most recent fiscal year, Simulations Plus reported gross margin of 58%, EBITDA margin of 28%, and net margin of (82%).

See estimated margins and future growth rates for Simulations Plus

Simulations Plus Margins

Last FY202420252026202720282029
Gross Margin58%60%60%64%
EBITDA Margin28%17%22%28%
EBIT Margin8%9%11%16%
Net Margin(82%)(20%)(50%)11%
FCF Margin18%15%18%-

Simulations Plus Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth3%16%10%4%
Gross Profit Growth14%(5%)9%11%
EBITDA Growth3%(11%)36%35%
EBIT Growth102%(20%)39%56%
Net Profit Growth(114%)(250%)169%(123%)
FCF Growth-(27%)33%-

Data powered by FactSet, Inc. and Morningstar, Inc.

Simulations Plus Operational KPIs

Simulations Plus' revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.

Simulations Plus' Rule of 40 is 32% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Simulations Plus' Rule of X is 38% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Simulations Plus
LTMLast FY202320242025202620272028
Rule of 4033%32%---
Bessemer Rule of X41%38%---
Revenue per Employee-$0.4M---
Opex per Employee-$0.2M---
S&M Expenses to Revenue15%15%14%14%15%
G&A Expenses to Revenue22%26%35%30%24%
R&D Expenses to Revenue14%9%8%8%11%
Opex to Revenue-50%61%52%50%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Simulations Plus Competitors

Simulations Plus competitors include Vitalhub, Software Service, Kneat, Ascom, Medical Data Vision, Beijing Sunwayworld, Optima Health, AdvancedAdvT, Medley Inc. and Spok.

Most Simulations Plus public comparables operate across Healthcare Software, B2B SaaS, Vertical SaaS, HealthTech and BioTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Vitalhub3.2x3.0x13.2x11.7x
Software Service0.8x0.8x3.6x4.9x
Kneat7.9x7.2x33.0x43.0x
Ascom0.7x0.7x5.9x6.0x
Medical Data Vision-9.2x--
Beijing Sunwayworld6.5x-112.1x-
Optima Health2.0x1.6x12.1x11.0x
AdvancedAdvT2.6x-11.0x-

This data is available for Pro users. Sign up to see all Simulations Plus competitors and their valuation data.

Start Free Trial

Acquisitions by Simulations Plus

Simulations Plus has acquired 5 companies to date.

Last acquisition by Simulations Plus was on June 12th 2024. Simulations Plus acquired Pro-ficiency for $100M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Simulations Plus

Pro-ficiency
Immunetrics
Lixoft
DILIsym Services
Description
Pro-ficiency is a provider of tech-enabled training platforms for clinical trials. North Carolina-headquartered, the company offers virtual simulators, compliance monitoring dashboards, and predictive analytics for site staff certification. Used by pharmaceutical sponsors like Pfizer, its tools track protocol adherence across global studies with real-time dashboards.
Immunetrics is a Pittsburgh-based biosimulation company that builds quantitative systems pharmacology models for immunology drug development. It simulates cytokine networks, immune cell dynamics, and disease progression to predict clinical outcomes. Platforms support portfolio decisions for rheumatoid arthritis, psoriasis, and lupus therapies. Immunetrics partners with pharmaceutical firms to refine dosing regimens and identify patient subsets via mechanistic modeling.
-
DILIsym Services is a Research Triangle Park-headquartered company founded in 2015 that develops DILIsym software for quantitative systems toxicology, enabling pharmaceutical companies to predict drug-induced liver injury risks during preclinical and clinical stages. The firm acquired intellectual property from the former Hamner Institutes and provides consulting services to optimize drug development pipelines. DILIsym integrates physiologically based pharmacokinetic modeling with liver safety data, serving clients in the biopharmaceutical sector worldwide.
HQ CountryUnited StatesUnited StatesFranceUnited States
HQ City
Raleigh, NC
Pittsburgh, PA
-
Durham, NC
Deal Date12 Jun 202420 Jun 20233 Apr 20201 May 2017
Valuation$100M$16M$17M$10M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Simulations Plus acquisitions and their M&A valuation multiples.

Start Free Trial

Investments by Simulations Plus

Simulations Plus has invested in 1 company to date.

Latest investment by Simulations Plus was on July 14th 2025. Simulations Plus invested in Nurocor in their $1M Seed round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by Simulations Plus

Nurocor
Description
Nurocor is a life sciences software provider offering a platform that digitizes clinical trial processes from protocol design to regulatory submission. San Francisco-headquartered, the company streamlines data management and analytics for biopharma firms to accelerate drug approvals.
HQ CountryUnited States
HQ City
Austin, TX
Deal Date14 Jul 2025
RoundSeed
Raised$1M
InvestorsSimulations Plus
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Simulations Plus investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Simulations Plus

When was Simulations Plus founded?Simulations Plus was founded in 1996.
Where is Simulations Plus headquartered?Simulations Plus is headquartered in United States.
How many employees does Simulations Plus have?As of today, Simulations Plus has over 213 employees.
Who is the CEO of Simulations Plus?Simulations Plus' CEO is Shawn O’Connor.
Is Simulations Plus publicly listed?Yes, Simulations Plus is a public company listed on Nasdaq.
What is the stock symbol of Simulations Plus?Simulations Plus trades under SLP ticker.
When did Simulations Plus go public?Simulations Plus went public in 1997.
Who are competitors of Simulations Plus?Simulations Plus main competitors include Vitalhub, Software Service, Kneat, Ascom, Medical Data Vision, Beijing Sunwayworld, Optima Health, AdvancedAdvT, Medley Inc., Spok.
What is the current market cap of Simulations Plus?Simulations Plus' current market cap is $339M.
What is the current revenue of Simulations Plus?Simulations Plus' last 12 months revenue is $81M.
What is the current revenue growth of Simulations Plus?Simulations Plus revenue growth (NTM/LTM) is 5%.
What is the current EV/Revenue multiple of Simulations Plus?Current revenue multiple of Simulations Plus is 3.7x.
What is the current EBITDA of Simulations Plus?Simulations Plus' last 12 months EBITDA is $22M.
What is Simulations Plus' EBITDA margin?Simulations Plus' last 12 months EBITDA margin is 28%.
What is the current EV/EBITDA multiple of Simulations Plus?Current EBITDA multiple of Simulations Plus is 13.2x.
How many companies Simulations Plus has acquired to date?As of June 2026, Simulations Plus has acquired 5 companies.
In how many companies Simulations Plus has invested to date?As of June 2026, Simulations Plus has invested in 1 company.
What was the last Simulations Plus investment?On 14th July 2025 Simulations Plus invested in Nurocor, participating in a $1M Seed round.
In what companies Simulations Plus invested in?Simulations Plus invested in Nurocor.

See public comps similar to Simulations Plus

Lists including Simulations Plus

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial